{
    "Clinical Trial ID": "NCT00121992",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm A: FAC",
        "  FAC (5-fluorouracil, doxorubicin, cyclophosphamide): 5-fluorouracil 500 mg/m2 iv on day 1, each 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv",
        "  5-fluorouracil",
        "  Doxorubicin",
        "Cyclophosphamide",
        "INTERVENTION 2: ",
        "  Arm B: TAC",
        "  TAC (docetaxel, doxorubicin, cyclophosphamide): Docetaxel 75 mg/m2 iv on day 1, each 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv",
        "  Docetaxel",
        "  Doxorubicin",
        "Cyclophosphamide"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Written informed consent",
        "  Operable breast cancer patients (T1-T3) with negative axillary lymph nodes (10 axillary nodes dissection) and high risk criteria according to St. Gallen consensus criteria.",
        "  Histologically proven breast cancer. Interval between surgery and registration is less than 60 days.",
        "  Definitive surgical treatment must be either mastectomy, or breast conservative surgery. Margins of resected specimen from surgery must be histologically free of invasive adenocarcinoma and ductal carcinoma in-situ (DCIS). Lobular carcinoma in-situ is not considered as positive margin.",
        "  Patients without proven metastatic disease.",
        "  Estrogen and progesterone receptors performed on the primary tumour prior to randomization.",
        "  Age between 18 years and 70 years.",
        "  Karnofsky performance status index > 80 %.",
        "  Adequate hepatic, renal and heart functions.",
        "  Adequate hematology levels.",
        "  Negative pregnancy test",
        "Exclusion Criteria:",
        "  Prior systemic anticancer therapy for breast cancer (immunotherapy, hormonotherapy, chemotherapy).",
        "  Prior anthracycline therapy or taxoids (paclitaxel, docetaxel) for any malignancy.",
        "  Prior radiation therapy for breast cancer.",
        "  Bilateral invasive breast cancer.",
        "  Pregnant, or lactating patients.",
        "  Patients of childbearing potential must implement adequate non-hormonal contraceptive measures during study treatment .",
        "  Any T4 or N1-3 or M1 breast cancer.",
        "  Pre-existing motor or sensory neurotoxicity of a severity grade 2 by NCI criteria.",
        "  Other serious illness or medical condition",
        "  Past or current history of neoplasm other than breast carcinoma.",
        "  Ipsilateral ductal carcinoma in-situ (DCIS) of the breast.",
        "  Lobular carcinoma in-situ (LCIS) of the breast.",
        "  Chronic treatment with corticosteroids unless initiated > 6 months prior to study entry and at low dose",
        "  Concurrent treatment with ovarian hormonal replacement therapy. Prior treatment should be stopped before study entry.",
        "  Definite contraindications for the use of corticosteroids.",
        "  Concurrent treatment with other experimental drugs.",
        "  Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry.",
        "  Concurrent treatment with any other anti-cancer therapy.",
        "Male patients."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Disease-free Survival (DFS) Events",
        "  DFS is calculated from the date of randomization until the first date of recurrence local, regional or distant, second primary tumor or death.",
        "  Time frame: 10 years",
        "Results 1: ",
        "  Arm/Group Title: Arm A: FAC",
        "  Arm/Group Description: FAC (5-fluorouracil, doxorubicin, cyclophosphamide): 5-fluorouracil 500 mg/m2 iv on day 1, each 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv",
        "  5-fluorouracil",
        "  Doxorubicin",
        "  Cyclophosphamide",
        "  Overall Number of Participants Analyzed: 521",
        "  Measure Type: Number",
        "  Unit of Measure: events  127",
        "Results 2: ",
        "  Arm/Group Title: Arm B: TAC",
        "  Arm/Group Description: TAC (docetaxel, doxorubicin, cyclophosphamide): Docetaxel 75 mg/m2 iv on day 1, each 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv",
        "  Docetaxel",
        "  Doxorubicin",
        "  Cyclophosphamide",
        "  Overall Number of Participants Analyzed: 539",
        "  Measure Type: Number",
        "  Unit of Measure: events  112"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 21/519 (4.05%)",
        "  Anaemia 1/519 (0.19%)",
        "  Blood bilirubin 0/519 (0.00%)",
        "  Leukopenia 0/519 (0.00%)",
        "  Neutropenia 1/519 (0.19%)",
        "  Arrhythmia 0/519 (0.00%)",
        "  Carotid artery thrombosis 1/519 (0.19%)",
        "  Ear infection 0/519 (0.00%)",
        "  Conjunctivitis 0/519 (0.00%)",
        "  Abdominal pain 1/519 (0.19%)",
        "  Anal fissure 0/519 (0.00%)",
        "  Constipation 0/519 (0.00%)",
        "  Diarrhoea 1/519 (0.19%)",
        "Adverse Events 2:",
        "  Total: 119/532 (22.37%)",
        "  Anaemia 1/532 (0.19%)",
        "  Blood bilirubin 1/532 (0.19%)",
        "  Leukopenia 1/532 (0.19%)",
        "  Neutropenia 5/532 (0.94%)",
        "  Arrhythmia 1/532 (0.19%)",
        "  Carotid artery thrombosis 0/532 (0.00%)",
        "  Ear infection 1/532 (0.19%)",
        "  Conjunctivitis 1/532 (0.19%)",
        "  Abdominal pain 1/532 (0.19%)",
        "  Anal fissure 1/532 (0.19%)",
        "  Constipation 1/532 (0.19%)",
        "  Diarrhoea 6/532 (1.13%)"
    ]
}